Skip to main content

Advertisement

Log in

Von Hippel–Lindau disease: a single gene, several hereditary tumors

  • Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

The Von Hippel–Lindau (VHL) disease is an autosomal dominant disorder characterized by the predisposition for multiple tumors caused by germline mutations in the tumor suppressor gene VHL. This disease is associated with a high morbidity and mortality and presents a variable expression, with different phenotypes from family to family, affecting different organs during the lifetime. The main manifestations of VHL are hemangioblastomas of the central nervous system and retina, renal carcinomas and cysts, bilateral pheochromocytomas, cystic and solid tumors of the pancreas, cystadenomas of the epididymis, and endolymphatic sac tumors. The discovery of any of the syndrome components should raise suspicion of this disease and other stigmas must then be investigated. Due to the complexities associated with management of the various VHL manifestation, the diagnosis and the follow-up of this syndrome is a challenge in the clinical practice and a multidisciplinary approach is needed. The particular relevance to endocrinologists is the detection of pheochromocytomas in 35% and islet cell tumors in 17% of VHL patients, which can be associated with hypertension, hypoglycemia, cardiac arrhythmias, and carcinoid syndrome. The purpose of this review is to define the Von Hippel–Lindau syndrome addressing its clinical aspects and classification, the importance of genetic counseling and to propose a protocol for clinical follow-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Rasmussen A, Alonso E, Ochoa A, De Biase I, Familiar I, Yescas P, Sosa AL, Rodriguez Y, Chavez M, Lopez-Lopez M, Bidichandani SI (2010) Uptake of genetic testing and long-term tumor surveillance in Von Hippel–Lindau disease. BMC Med Genet 11:4. doi:10.1186/1471-2350-11-4

    Article  PubMed  PubMed Central  Google Scholar 

  2. Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-Smith MA (1990) Clinical features and natural history of Von Hippel–Lindau disease. Q J Med 77(283):1151–1163

    Article  CAS  PubMed  Google Scholar 

  3. Maher ER, Neumann HP, Richard S (2011) Von Hippel–Lindau disease: a clinical and scientific review. Eur J Hum Genet 19(6):617–623. doi:10.1038/ejhg.2010.175

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Friedrich CA (1999) Von Hippel–Lindau syndrome. A pleomorphic condition. Cancer 86(11 Suppl):2478–2482

    Article  CAS  PubMed  Google Scholar 

  5. Kaelin WG (2007) Von Hippel–Lindau disease. Annu Rev Pathol 2:145–173. doi:10.1146/annurev.pathol.2.010506.092049

    Article  CAS  PubMed  Google Scholar 

  6. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733):271–275. doi:10.1038/20459

    Article  CAS  PubMed  Google Scholar 

  7. Semenza GL (2011) Oxygen sensing, homeostasis, and disease. N Engl J Med 365(6):537–547. doi:10.1056/NEJMra1011165

    Article  CAS  PubMed  Google Scholar 

  8. Frew IJ, Krek W (2008) pVHL: a multipurpose adaptor protein. Sci Signal 1(24):pe30. doi:10.1126/scisignal.124pe30

    Article  PubMed  Google Scholar 

  9. Gerdes JM, Davis EE, Katsanis N (2009) The vertebrate primary cilium in development, homeostasis, and disease. Cell 137(1):32–45. doi:10.1016/j.cell.2009.03.023

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Barontini M, Dahia PL (2010) VHL disease. Best Pract Res Clin Endocrinol Metab 24(3):401–413. doi:10.1016/j.beem.2010.01.002

    Article  CAS  PubMed  Google Scholar 

  11. Musacchio A, Salmon ED (2007) The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 8(5):379–393. doi:10.1038/nrm2163

    Article  CAS  PubMed  Google Scholar 

  12. Thoma CR, Toso A, Gutbrodt KL, Reggi SP, Frew IJ, Schraml P, Hergovich A, Moch H, Meraldi P, Krek W (2009) VHL loss causes spindle misorientation and chromosome instability. Nat Cell Biol 11(8):994–1001. doi:10.1038/ncb1912

    Article  CAS  PubMed  Google Scholar 

  13. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH (2003) Von Hippel–Lindau disease. Lancet 361(9374):2059–2067. doi:10.1016/S0140-6736(03)13643-4

    Article  CAS  PubMed  Google Scholar 

  14. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L et al (1993) Identification of the Von Hippel–Lindau disease tumor suppressor gene. Science 260(5112):1317–1320

    Article  CAS  PubMed  Google Scholar 

  15. Couch V, Lindor NM, Karnes PS, Michels VV (2000) Von Hippel–Lindau disease. Mayo Clin Proc 75(3):265–272

    Article  CAS  PubMed  Google Scholar 

  16. Nordstrom-O’Brien M, van der Luijt RB, van Rooijen E, van den Ouweland AM, Majoor-Krakauer DF, Lolkema MP, van Brussel A, Voest EE, Giles RH (2010) Genetic analysis of Von Hippel–Lindau disease. Hum Mutat 31(5):521–537. doi:10.1002/humu.21219

    PubMed  Google Scholar 

  17. Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B (1995) Von Hippel–Lindau disease: genetic, clinical, and imaging features. Radiology 194(3):629–642

    Article  CAS  PubMed  Google Scholar 

  18. Neumann HP, Eggert HR, Scheremet R, Schumacher M, Mohadjer M, Wakhloo AK, Volk B, Hettmannsperger U, Riegler P, Schollmeyer P et al (1992) Central nervous system lesions in Von Hippel–Lindau syndrome. J Neurol Neurosurg Psychiatry 55(10):898–901

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Lonser RR, Butman JA, Huntoon K, Asthagiri AR, Wu T, Bakhtian KD, Chew EY, Zhuang Z, Linehan WM, Oldfield EH (2014) Prospective natural history study of central nervous system hemangioblastomas in Von Hippel–Lindau disease. J Neurosurg 120(5):1055–1062. doi:10.3171/2014.1.JNS131431

    Article  PubMed  PubMed Central  Google Scholar 

  20. Wiesener MS, Seyfarth M, Warnecke C, Jurgensen JS, Rosenberger C, Morgan NV, Maher ER, Frei U, Eckardt KU (2002) Paraneoplastic erythrocytosis associated with an inactivating point mutation of the Von Hippel–Lindau gene in a renal cell carcinoma. Blood 99(10):3562–3565

    Article  CAS  PubMed  Google Scholar 

  21. Asthagiri AR, Mehta GU, Zach L, Li X, Butman JA, Camphausen KA, Lonser RR (2010) Prospective evaluation of radiosurgery for hemangioblastomas in Von Hippel–Lindau disease. Neuro Oncol 12(1):80–86. doi:10.1093/neuonc/nop018

    Article  PubMed  PubMed Central  Google Scholar 

  22. Patrice SJ, Sneed PK, Flickinger JC, Shrieve DC, Pollock BE, Alexander E 3rd, Larson DA, Kondziolka DS, Gutin PH, Wara WM, McDermott MW, Lunsford LD, Loeffler JS (1996) Radiosurgery for hemangioblastoma: results of a multiinstitutional experience. Int J Radiat Oncol Biol Phys 35(3):493–499

    Article  CAS  PubMed  Google Scholar 

  23. Wanebo JE, Lonser RR, Glenn GM, Oldfield EH (2003) The natural history of hemangioblastomas of the central nervous system in patients with Von Hippel–Lindau disease. J Neurosurg 98(1):82–94. doi:10.3171/jns.2003.98.1.0082

    Article  PubMed  Google Scholar 

  24. Huntoon K, Wu T, Elder JB, Butman JA, Chew EY, Linehan WM, Oldfield EH, Lonser RR (2016) Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in Von Hippel–Lindau disease. J Neurosurg 124(4):971–976. doi:10.3171/2015.4.JNS1533

    Article  PubMed  Google Scholar 

  25. Kreusel KM (2005) Ophthalmological manifestations in VHL and NF 1: pathological and diagnostic implications. Fam Cancer 4(1):43–47. doi:10.1007/s10689-004-1327-0

    Article  PubMed  Google Scholar 

  26. Singh AD, Nouri M, Shields CL, Shields JA, Smith AF (2001) Retinal capillary hemangioma: a comparison of sporadic cases and cases associated with Von Hippel–Lindau disease. Ophthalmology 108(10):1907–1911

    Article  CAS  PubMed  Google Scholar 

  27. Schoen MA, Shields CL, Say EA, Douglass AM, Shields JA, Jampol LM (2016) Clinically invisible retinal hemangioblastomas detected by spectral domain optical coherence tomography and fluorescein angiography in twins. Retin Cases Brief Rep. doi:10.1097/ICB.0000000000000382

    Google Scholar 

  28. Singh AD, Nouri M, Shields CL, Shields JA, Perez N (2002) Treatment of retinal capillary hemangioma. Ophthalmology 109(10):1799–1806

    Article  PubMed  Google Scholar 

  29. Linehan WM, Walther MM, Zbar B (2003) The genetic basis of cancer of the kidney. J Urol 170(6 Pt 1):2163–2172. doi:10.1097/01.ju.0000096060.92397.ed

    Article  CAS  PubMed  Google Scholar 

  30. Kragel PJ, Walther MM, Pestaner JP, Filling-Katz MR (1991) Simple renal cysts, atypical renal cysts, and renal cell carcinoma in Von Hippel–Lindau disease: a lectin and immunohistochemical study in six patients. Mod Pathol 4(2):210–214

    CAS  PubMed  Google Scholar 

  31. Neumann HP, Zbar B (1997) Renal cysts, renal cancer and Von Hippel–Lindau disease. Kidney Int 51(1):16–26

    Article  CAS  PubMed  Google Scholar 

  32. Montani M, Heinimann K, von Teichman A, Rudolph T, Perren A, Moch H (2010) VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in Von Hippel–Lindau disease. Am J Surg Pathol 34(6):806–815. doi:10.1097/PAS.0b013e3181ddf54d

    Article  PubMed  Google Scholar 

  33. Malek RS, Omess PJ, Benson RC Jr, Zincke H (1987) Renal cell carcinoma in Von Hippel–Lindau syndrome. Am J Med 82(2):236–238

    Article  CAS  PubMed  Google Scholar 

  34. Choyke PL, Glenn GM, Walther MM, Zbar B, Weiss GH, Alexander RB, Hayes WS, Long JP, Thakore KN, Linehan WM (1992) The natural history of renal lesions in Von Hippel–Lindau disease: a serial CT study in 28 patients. AJR Am J Roentgenol 159(6):1229–1234

    Article  CAS  PubMed  Google Scholar 

  35. Nelson JB, Oyasu R, Dalton DP (1994) The clinical and pathological manifestations of renal tumors in Von Hippel–Lindau disease. J Urol 152(6 Pt 2):2221–2226

    Article  CAS  PubMed  Google Scholar 

  36. Karsdorp N, Elderson A, Wittebol-Post D, Hene RJ, Vos J, Feldberg MA, van Gils AP, Jansen-Schillhorn van Veen JM, Vroom TM, Hoppener JW et al (1994) Von Hippel–Lindau disease: new strategies in early detection and treatment. Am J Med 97(2):158–168

    Article  CAS  PubMed  Google Scholar 

  37. Chauveau D, Duvic C, Chretien Y, Paraf F, Droz D, Melki P, Helenon O, Richard S, Grunfeld JP (1996) Renal involvement in Von Hippel–Lindau disease. Kidney Int 50(3):944–951

    Article  CAS  PubMed  Google Scholar 

  38. Steinbach F, Novick AC, Zincke H, Miller DP, Williams RD, Lund G, Skinner DG, Esrig D, Richie JP, deKernion JB et al (1995) Treatment of renal cell carcinoma in Von Hippel–Lindau disease: a multicenter study. J Urol 153(6):1812–1816

    Article  CAS  PubMed  Google Scholar 

  39. Koch CA, Mauro D, Walther MM, Linehan WM, Vortmeyer AO, Jaffe R, Pacak K, Chrousos GP, Zhuang Z, Lubensky IA (2002) Pheochromocytoma in Von Hippel–Lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocr Pathol 13(1):17–27

    Article  CAS  PubMed  Google Scholar 

  40. Pinato DJ, Ramachandran R, Toussi ST, Vergine M, Ngo N, Sharma R, Lloyd T, Meeran K, Palazzo F, Martin N, Khoo B, Dina R, Tan TM (2013) Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. Br J Cancer 108(2):429–437. doi:10.1038/bjc.2012.538

    Article  CAS  PubMed  Google Scholar 

  41. Baghai M, Thompson GB, Young WF Jr, Grant CS, Michels VV, van Heerden JA (2002) Pheochromocytomas and paragangliomas in Von Hippel–Lindau disease: a role for laparoscopic and cortical-sparing surgery. Arch Surg 137(6):682–688 (discussion 688–689)

    Article  PubMed  Google Scholar 

  42. Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B, Kirste G (1993) Pheochromocytomas, multiple endocrine neoplasia type 2, and Von Hippel–Lindau disease. N Engl J Med 329(21):1531–1538. doi:10.1056/NEJM199311183292103

    Article  CAS  PubMed  Google Scholar 

  43. Aufforth RD, Ramakant P, Sadowski SM, Mehta A, Trebska-McGowan K, Nilubol N, Pacak K, Kebebew E (2015) Pheochromocytoma screening initiation and frequency in Von Hippel–Lindau syndrome. J Clin Endocrinol Metab 100(12):4498–4504. doi:10.1210/jc.2015-3045

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Cassol C, Mete O (2015) Endocrine manifestations of Von Hippel–Lindau disease. Arch Pathol Lab Med 139(2):263–268. doi:10.5858/arpa.2013-0520-RS

    Article  PubMed  Google Scholar 

  45. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G et al (1995) Germline mutations in the Von Hippel–Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5(1):66–75. doi:10.1002/humu.1380050109

    Article  CAS  PubMed  Google Scholar 

  46. Eisenhofer G, Walther MM, Huynh TT, Li ST, Bornstein SR, Vortmeyer A, Mannelli M, Goldstein DS, Linehan WM, Lenders JW, Pacak K (2001) Pheochromocytomas in Von Hippel–Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 86(5):1999–2008

    Article  CAS  PubMed  Google Scholar 

  47. Baguet JP, Hammer L, Mazzuco TL, Chabre O, Mallion JM, Sturm N, Chaffanjon P (2004) Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol 150(5):681–686

    Article  CAS  PubMed  Google Scholar 

  48. Green JS, Bowmer MI, Johnson GJ (1986) Von Hippel–Lindau disease in a Newfoundland kindred. CMAJ 134(2):133–138, 146

  49. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr, Endocrine S (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(6):1915–1942. doi:10.1210/jc.2014-1498

    Article  CAS  PubMed  Google Scholar 

  50. Gaal J, van Nederveen FH, Erlic Z, Korpershoek E, Oldenburg R, Boedeker CC, Kontny U, Neumann HP, Dinjens WN, de Krijger RR (2009) Parasympathetic paragangliomas are part of the Von Hippel–Lindau syndrome. J Clin Endocrinol Metab 94(11):4367–4371. doi:10.1210/jc.2009-1479

    Article  CAS  PubMed  Google Scholar 

  51. Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM, Chauveau D, Balian A, Beigelman C, O’Toole D, Bernades P, Ruszniewski P, Richard S (2000) Pancreatic involvement in Von Hippel–Lindau disease. The Groupe Francophone d’Etude de la Maladie de Von Hippel–Lindau. Gastroenterology 119(4):1087–1095

    Article  CAS  PubMed  Google Scholar 

  52. Charlesworth M, Verbeke CS, Falk GA, Walsh M, Smith AM, Morris-Stiff G (2012) Pancreatic lesions in Von Hippel–Lindau disease? A systematic review and meta-synthesis of the literature. J Gastrointest Surg 16(7):1422–1428. doi:10.1007/s11605-012-1847-0

    Article  PubMed  Google Scholar 

  53. Corcos O, Couvelard A, Giraud S, Vullierme MP, Dermot OT, Rebours V, Stievenart JL, Penfornis A, Niccoli-Sire P, Baudin E, Sauvanet A, Levy P, Ruszniewski P, Richard S, Hammel P (2008) Endocrine pancreatic tumors in Von Hippel–Lindau disease: clinical, histological, and genetic features. Pancreas 37(1):85–93. doi:10.1097/MPA.0b013e31815f394a

    Article  CAS  PubMed  Google Scholar 

  54. Mete O, Asa SL (2013) Precursor lesions of endocrine system neoplasms. Pathology 45(3):316–330. doi:10.1097/PAT.0b013e32835f45c5

    Article  CAS  PubMed  Google Scholar 

  55. Lubensky IA, Pack S, Ault D, Vortmeyer AO, Libutti SK, Choyke PL, Walther MM, Linehan WM, Zhuang Z (1998) Multiple neuroendocrine tumors of the pancreas in Von Hippel–Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol 153(1):223–231. doi:10.1016/S0002-9440(10)65563-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Gucer H, Szentgyorgyi E, Ezzat S, Asa SL, Mete O (2013) Inhibin-expressing clear cell neuroendocrine tumor of the ampulla: an unusual presentation of Von Hippel–Lindau disease. Virchows Arch 463(4):593–597. doi:10.1007/s00428-013-1465-6

    Article  CAS  PubMed  Google Scholar 

  57. Keutgen XM, Hammel P, Choyke PL, Libutti SK, Jonasch E, Kebebew E (2016) Evaluation and management of pancreatic lesions in patients with Von Hippel–Lindau disease. Nat Rev Clin Oncol 13(9):537–549. doi:10.1038/nrclinonc.2016.37

    Article  CAS  PubMed  Google Scholar 

  58. Vinik AI, Raymond E (2013) Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib. Therap Adv Gastroenterol 6(5):396–411. doi:10.1177/1756283X13493878

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, Seidel G, Shutack Y, Yuldasheva N, Eugeni M, Bartlett DL, Glenn GM, Middelton L, Linehan WM, Libutti SK (2007) Clinical, genetic and radiographic analysis of 108 patients with Von Hippel–Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 142(6):814–818. doi:10.1016/j.surg.2007.09.012 (discussion 818 e811–e812)

    Article  PubMed  Google Scholar 

  60. Manski TJ, Heffner DK, Glenn GM, Patronas NJ, Pikus AT, Katz D, Lebovics R, Sledjeski K, Choyke PL, Zbar B, Linehan WM, Oldfield EH (1997) Endolymphatic sac tumors. A source of morbid hearing loss in Von Hippel–Lindau disease. JAMA 277(18):1461–1466

    Article  CAS  PubMed  Google Scholar 

  61. Butman JA, Kim HJ, Baggenstos M, Ammerman JM, Dambrosia J, Patsalides A, Patronas NJ, Oldfield EH, Lonser RR (2007) Mechanisms of morbid hearing loss associated with tumors of the endolymphatic sac in Von Hippel–Lindau disease. JAMA 298(1):41–48. doi:10.1001/jama.298.1.41

    Article  CAS  PubMed  Google Scholar 

  62. Hansen MR, Luxford WM (2004) Surgical outcomes in patients with endolymphatic sac tumors. Laryngoscope 114(8):1470–1474. doi:10.1097/00005537-200408000-00028

    Article  PubMed  Google Scholar 

  63. Kim HJ, Butman JA, Brewer C, Zalewski C, Vortmeyer AO, Glenn G, Oldfield EH, Lonser RR (2005) Tumors of the endolymphatic sac in patients with Von Hippel–Lindau disease: implications for their natural history, diagnosis, and treatment. J Neurosurg 102(3):503–512. doi:10.3171/jns.2005.102.3.0503

    Article  PubMed  Google Scholar 

  64. Safatle PP, Farage L, Sampaio A, Ferreira FA, Safatle HP, Oliveira CA, Ferrari I (2009) Endolymphatic sac tumor and Von Hippel–Lindau disease in a single family. Arq Neuropsiquiatr 67(4):1097–1099

    Article  PubMed  Google Scholar 

  65. Jagannathan J, Lonser RR, Stanger RA, Butman JA, Vortmeyer AO, Zalewski CK, Brewer C, Surowicz C, Kim HJ (2007) Cochlear implantation for hearing loss associated with bilateral endolymphatic sac tumors in Von Hippel–Lindau disease. Otol Neurotol 28(7):927–930. doi:10.1097/MAO.0b013e31805c7506

    PubMed  Google Scholar 

  66. Gersell DJ, King TC (1988) Papillary cystadenoma of the mesosalpinx in Von Hippel–Lindau disease. Am J Surg Pathol 12(2):145–149

    Article  CAS  PubMed  Google Scholar 

  67. Hes FJ, Hoppener JW, Luijt RB, Lips CJ (2005) Von Hippel–Lindau disease. Hered Cancer Clin Pract 3(4):171–178. doi:10.1186/1897-4287-3-4-171

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Schmid S, Gillessen S, Binet I, Brandle M, Engeler D, Greiner J, Hader C, Heinimann K, Kloos P, Krek W, Krull I, Stoeckli SJ, Sulz MC, van Leyen K, Weber J, Rothermundt C, Hundsberger T (2014) Management of Von Hippel–Lindau disease: an interdisciplinary review. Oncol Res Treat 37(12):761–771. doi:10.1159/000369362

    Article  CAS  PubMed  Google Scholar 

  69. Obradors A, Fernandez E, Rius M, Oliver-Bonet M, Martinez-Fresno M, Benet J, Navarro J (2009) Outcome of twin babies free of Von Hippel–Lindau disease after a double-factor preimplantation genetic diagnosis: monogenetic mutation analysis and comprehensive aneuploidy screening. Fertil Steril 91(3):933, e931–937. doi:10.1016/j.fertnstert.2008.11.013

  70. Nielsen SM, Rhodes L, Blanco I, Chung WK, Eng C, Maher ER, Richard S, Giles RH (2016) Von Hippel–Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome. J Clin Oncol 34(18):2172–2181. doi:10.1200/JCO.2015.65.6140

    Article  CAS  PubMed  Google Scholar 

  71. Maher ER, Bentley E, Payne SJ, Latif F, Richards FM, Chiano M, Hosoe S, Yates JR, Linehan M, Barton DE et al (1992) Presymptomatic diagnosis of Von Hippel–Lindau disease with flanking DNA markers. J Med Genet 29(12):902–905

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V, Pan-Cancer Working G (2015) Targeted therapy for genetic cancer syndromes: Von Hippel–Lindau disease, Cowden syndrome, and Proteus syndrome. Discov Med 19(103):109–116

    PubMed  Google Scholar 

  73. Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144–2150. doi:10.1200/JCO.2009.26.7849

    Article  CAS  PubMed  Google Scholar 

  74. Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, Tannir NM, Gombos DS, Fuller GN, Matin SF (2011) Pilot trial of sunitinib therapy in patients with Von Hippel–Lindau disease. Ann Oncol 22(12):2661–2666. doi:10.1093/annonc/mdr011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Kim BY, Jonasch E, McCutcheon IE (2012) Pazopanib therapy for cerebellar hemangioblastomas in Von Hippel–Lindau disease: case report. Target Oncol 7(2):145–149. doi:10.1007/s11523-012-0214-0

    Article  PubMed  PubMed Central  Google Scholar 

  76. Hrisomalos FN, Maturi RK, Pata V (2010) Long-term use of intravitreal bevacizumab (avastin) for the treatment of Von Hippel–Lindau associated retinal hemangioblastomas. Open Ophthalmol J 4:66–69. doi:10.2174/1874364101004010066

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Battelli C, Cho DC (2011) mTOR inhibitors in renal cell carcinoma. Therapy 8(4):359–367. doi:10.2217/thy.11.32

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5(8):671–688. doi:10.1038/nrd2062

    Article  CAS  PubMed  Google Scholar 

  79. Yim KL (2012) Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors. Cancer Manag Res 4:207–214. doi:10.2147/CMAR.S25979

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We are grateful to Milaydis Sosa for proofreading.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D. Pignatelli.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human subjects performed by any of the authors

Informed consent

No informed consent.

Grants

This study was supported by the Portuguese Foundation for Science and Technology (FCT) through a PhD grant to Sofia S. Pereira (SFRH/BD/89308/2012).

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 252 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crespigio, J., Berbel, L.C.L., Dias, M.A. et al. Von Hippel–Lindau disease: a single gene, several hereditary tumors. J Endocrinol Invest 41, 21–31 (2018). https://doi.org/10.1007/s40618-017-0683-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-017-0683-1

Keywords

Navigation